# Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

> **NCT02430909** · PHASE2 · COMPLETED · sponsor: **UCB Celltech** · enrollment: 159 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Bimekizumab
- **BIOLOGICAL:** Certolizumab Pegol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02430909
- **Lead sponsor:** UCB Celltech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2017-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02430909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02430909, "Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02430909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*